These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7060325)

  • 21. Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy.
    Canada AT; Lesko LJ; Haffajee CI; Johnson B; Asdourian GK
    Drug Intell Clin Pharm; 1983 Feb; 17(2):100-4. PubMed ID: 6337802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of amiodarone in rats.
    Riva E; Gerna M; Neyroz P; Urso R; Bartosek I; Guaitani A
    J Cardiovasc Pharmacol; 1982; 4(2):270-5. PubMed ID: 6175811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amiodarone: a unique antiarrhythmic agent.
    Sloskey GE
    Clin Pharm; 1983; 2(4):330-40. PubMed ID: 6349912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites.
    Stäubli M; Troendle A; Schmid B; Balmer P; Kohler B; Studer H; Bircher J
    Eur J Clin Pharmacol; 1985; 29(4):417-23. PubMed ID: 4092724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amiodarone and desethylamiodarone concentrations in plasma and tissues of surgically treated patients on long-term oral amiodarone treatment.
    Plomp TA; Hauer RN; Robles de Medina EO
    In Vivo; 1990; 4(2):97-100. PubMed ID: 2129806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of long-term oral amiodarone therapy.
    Pollak PT; Bouillon T; Shafer SL
    Clin Pharmacol Ther; 2000 Jun; 67(6):642-52. PubMed ID: 10872646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disposition of amiodarone and its proximate metabolite, desethylamiodarone, in the dog for oral administration of single-dose and short-term drug regimens.
    Brien JF; Jimmo S; Brennan FJ; Armstrong PW; Abdollah H
    Drug Metab Dispos; 1990; 18(6):846-51. PubMed ID: 1981527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amiodarone in the treatment of refractory ventricular arrhythmias. Importance and safety of initial high-dose therapy.
    Rakita L; Sobol SM
    JAMA; 1983 Sep; 250(10):1293-5. PubMed ID: 6348310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue distribution of amiodarone and desethylamiodarone in rats after multiple intraperitoneal administration of various amiodarone dosages.
    Plomp TA; Wiersinga WM; Maes RA
    Arzneimittelforschung; 1985; 35(1):122-9. PubMed ID: 4039141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity.
    Stäubli M; Bircher J; Galeazzi RL; Remund H; Studer H
    Eur J Clin Pharmacol; 1983; 24(4):485-94. PubMed ID: 6861863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amiodarone dosing: a proposal based on its pharmacokinetics.
    Siddoway LA; McAllister CB; Wilkinson GR; Roden DM; Woosley RL
    Am Heart J; 1983 Oct; 106(4 Pt 2):951-6. PubMed ID: 6613842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacokinetics of the newer antiarrhythmic agents.
    Gillis AM; Kates RE
    Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue extraction of amiodarone and N-desethylamiodarone in man after a single oral dose.
    Berdeaux A; Roche A; Labaille T; Giroux B; Edouard A; Giudicelli JF
    Br J Clin Pharmacol; 1984 Nov; 18(5):759-63. PubMed ID: 6508984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic characteristics of amiodarone in long-term oral therapy in Japanese population.
    Kashima A; Funahashi M; Fukumoto K; Komamura K; Kamakura S; Kitakaze M; Ueno K
    Biol Pharm Bull; 2005 Oct; 28(10):1934-8. PubMed ID: 16204949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal elimination of amiodarone and its desethyl metabolite.
    Harris L; Hind CR; McKenna WJ; Savage C; Krikler SJ; Storey GC; Holt DW
    Postgrad Med J; 1983 Jul; 59(693):440-2. PubMed ID: 6622326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications.
    Nademanee K; Kannan R; Hendrickson J; Ookhtens M; Kay I; Singh BN
    J Am Coll Cardiol; 1984 Jul; 4(1):111-6. PubMed ID: 6736437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Amiodarone therapy--behavior of serum and fatty tissue concentrations].
    Gonska BD; Bethge KP; Wagner H; Bosse K; Köbberling J; Quentin CD; Kreuzer H
    Klin Wochenschr; 1986 Mar; 64(5):219-26. PubMed ID: 3702280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of phenobarbitone on the pharmacokinetics and tissue levels of amiodarone in the rat.
    Fruncillo RJ; Bernhard R; Swanson BN; Vlasses PH; Ferguson RK
    J Pharm Pharmacol; 1985 Oct; 37(10):729-31. PubMed ID: 2867144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue uptake and metabolism of amiodarone after chronic administration in rabbits.
    Kannan R; Miller S; Singh BN
    Drug Metab Dispos; 1985; 13(6):646-50. PubMed ID: 2867865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of amiodarone on oral digoxin bioavailability in healthy volunteers.
    Maragno I; Santostasi G; Gaion RM; Paleari C
    Int J Clin Pharmacol Res; 1984; 4(2):149-53. PubMed ID: 6469441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.